Skip to main content

Table 2 Prevention of pre-eclampsia and management of pre-existing hypertension. Values are n (%)

From: An evaluation of the influence of the publication of the UK National Institute for health and Care Excellence’s guidance on hypertension in pregnancy: a retrospective analysis of clinical practice

 

NICE hypertension in pregnancy recommendations

P-valuea

P-valueb (CI)

Before guidance N = 1271

After guidance N = 1219

High risk of pre-eclampsia

73 (6)

93 (8)

0.06

0.05 (−0.01, 0.04)

Moderate risk of pre-eclampsia

105 (9)

116 (10)

0.20

0.40 (−0.03, 0.01)

N = 73

N = 93

  

Aspirin prescription for high risk women

10 (14)

50 (54)

< 0.01

< 0.01 (0.37, 0.43)

N = 105

N = 116

  

Aspirin prescription for moderate risk women

3 (3)

63 (54)

< 0.01

< 0.01 (0.48, 0.54)

Management of pre-existing hypertension

N = 1271

N = 1219

  

Diagnosis of pre-existing hypertension

17 (1)

41 (3)

< 0.01

< 0.01 (0.01, 0.03)

ACE or ARBs used prior to or in early pregnancy

2 (12)

10 (25)

0.30

0.27 (−0.07, 0.34)

N = 2

N = 10

  

Alternatives to ACE or ARBs prescribed

2 (100)

8 (80)

0.50

0.05 (−0.45, − 0.08)

  1. ACE Angiotensin-converting enzyme, ARB Angiotensin receptor blockers
  2. adifference in frequencies ‘before and after’ guidance publication
  3. bdifference in proportions ‘before and after’ guidance publication